You are here

osteoporosis

Consumer watchdog petitions FDA for black box warning on Amgen's Prolia

Consumer watchdog petitions FDA for black box warning on Amgen's Prolia

Fierce Pharma

spinal fractures

Flag link:

Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost

Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost

Endpoints

Flag link:

FDA approves Evenity for osteoporosis

FDA approves Evenity for osteoporosis

BioCentury

Flag link:

Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote

Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote

Fierce Pharma

advisory panels

Flag link:

FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials

FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials

Endpoints

clinical trials

Flag link:

Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead

Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead

Endpoints

Flag link:

Radius Health Initiates Phase III Trial of Osteoporosis Injection Drug for Males

Radius Health Initiates Phase III Trial of Osteoporosis Injection Drug for Males

CP Wire

clinical trials

Flag link:

Amgen rolls new Prolia osteoporosis ads, just weeks after next-gen Evenity hits a snag

Amgen rolls new Prolia osteoporosis ads, just weeks after next-gen Evenity hits a snag

Fierce Pharma

Flag link:

Payer coverage boosts Radius' Tymlos

Payer coverage boosts Radius' Tymlos

BioPharma Dive

Express Scripts

Flag link:

Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo

Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo

Fierce Pharma

Express Scripts

Flag link:

An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape

An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape

Seeking Alpha

Flag link:

FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO

FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO

Endpoints

Flag link:

Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug

Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug

Fierce Pharma

Flag link:

With Amgen hot on its heels, Radius races to get a jump on osteoporosis drug rivalry

With Amgen hot on its heels, Radius races to get a jump on osteoporosis drug rivalry

Endpoints

Flag link:

FDA approves Radius Health's osteoporosis drug Tymlos

FDA approves Radius Health's osteoporosis drug Tymlos

Yahoo/Reuters

Flag link:

Court Revives Claims Against Merck Osteoporosis Drug

Court Revives Claims Against Merck Osteoporosis Drug

Investopedia

thigh fractures

Flag link:

Radius shares slide after FDA delays decision on bone drug

Radius shares slide after FDA delays decision on bone drug

BioPharma Dive

Flag link:

Dr. Reddy's Labs Launches Generic Osteoporosis Drug Tablets in the US

Dr. Reddy's Labs Launches Generic Osteoporosis Drug Tablets in the US

Yahoo

Flag link:

Amgen's Osteoporosis Drug Crosses a Hurdle

Amgen's Osteoporosis Drug Crosses a Hurdle

Investopedia

Flag link:

Amgen’s expectations for romosozumab take a hit as Radius lines up its rival osteoporosis drug

Amgen’s expectations for romosozumab take a hit as Radius lines up its rival osteoporosis drug

Endpoints

Flag link:

Pages